Russian company Biocad filed a lawsuit against Deputy Head of the Ministry of Health Sergei Glagolev. With data In the files of arbitration cases, the case was discussed in the first instance court for four days.
In a comment for Forbes Biocad representatives explained that the official’s inaction prevented the company from including its drugs for the treatment of multiple sclerosis in the list of vital drugs and high-cost nosologies (VED).
Biocad requests a meeting of the departmental commission to consider the inclusion of its drugs in the list of vital and essential medicines for the “14 high-cost nosology” program.
It was noted that the last meeting of such a commission was held in February 2023, and its postponement deprived Biocad of the opportunity to “conduct an equal economic struggle with foreign manufacturers.”
This is before Biocad filed for the registration of a biosimilar of an oncology drug.
Previously at the Ministry of Health said About the threat of disease X.